Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
14,468 total articles
Nissan is cheap by conventional balance-sheet measures and is executing structural upgrades that can unlock margins and free cash flow over the next 6-12 months. This trade idea takes a constructive, risk-aware long stance with a clearly defined entry, stop and target and a 180-trading-day horizon to allow organizational changes and alliance-driven…
Microsoft is trading at $504.54 after a sustained recovery from the $349 52-week low. Fundamentals - $67B in free cash flow, ROE north of 30%, low leverage - back a thesis that the company can extend its rally. This is a mid-term swing trade: entry $504.54, stop $462.00, target $545.00 (45 trading days) with clear risk-management and contingent tri…
Qualcomm's shift from smartphones toward data-center AI chips is real and measurable. A major AWS deal and growing AI momentum justify a long trade with disciplined risk controls. This plan outlines why, how, and what could go wrong.
Trekor Metals (TGB) has moved from promise to production with the first Florence copper cathode harvest. The market is still pricing the company like a single-asset explorer despite a $2.85B market cap, multiple development-stage projects and improving cash flow potential. This trade idea takes a constructive stance: buy a defined position on weakn…
APi Group (APG) sits at the intersection of recurring life-safety services and infrastructure maintenance. With free cash flow of $676M, recent M&A adding ~$90M of revenue, and activist/insider interest, APG is positioned to monetize the infrastructure cycle through both organic service growth and bolt-on acquisitions. Technical indicators show nea…
Galderma’s heavy launch investments are starting to show in market momentum and expanding opportunity sets across rosacea, hyperpigmentation and aesthetic injectables. At a $45.5B market cap and a PE near 51, the stock already prices growth; I expect product ramps and margin expansion to drive a re-rating over the next 180 trading days, while keepi…
Bristow Group (VTOL) is a lean, cash-generating helicopter and aviation services contractor trading at roughly $1.27B market cap and a 12x P/E. With management keeping 2026 adjusted EBITDA guidance intact and recent top-line strength, the stock offers asymmetric upside from operating leverage. This trade idea outlines an entry at $42.76 with a clea…
Delta’s ownership of a refinery is more than PR - it meaningfully lowers jet fuel cost exposure, stabilizes margins and creates a tactical buying opportunity after recent weakness. This trade targets a rebound as crude volatility and improved refinery economics flow through to airline margins.
Adobe beat on Q3, raised guidance, and reported accelerating AI monetization, yet the stock trades at a depressed multiple and near-cycle cash generation that argue the worst-case AI outcome is already priced. This trade targets a mid-term rebound while limiting downside with a tight stop.
Saturn Oil's share price has tripled, but the underlying project economics and small-cap valuation still leave room for a disciplined long trade. The set-up works if near-term production and cash generation keep improving and if commodity fundamentals remain supportive. Trade plan included with entry at $1.50, stop at $1.00 and primary/secondary ta…
NRX Pharmaceuticals is a clinical-stage biotech focused on NMDA-platform therapies. With a preservative-free ketamine ANDA advancing toward potential approval, recent commercial preparation and a $20M follow-on raise, and an active short base, NRXP offers a high-risk, high-reward swing trade. Entry at $3.42, target $5.00, stop $2.60 — mid-term hori…
Berkshire Hathaway offers a compelling long trade right now: deep cash reserves, steady free cash flow, aggressive buybacks and a diversified business mix create asymmetric upside with limited downside. We'll lay out an entry, stop and target with time-horizon logic and clear risks.
Devon Energy is trading near $51 with a tidy balance sheet, attractive EV/EBITDA of 7.6x, and recent liability management tied to the Coterra deal. With oil prices likely to stay supportive and integration risk receding after a successful note exchange, this is a mid‑term long idea targeting $60 with a clear stop at $46.50.
Lifecore is a small-cap CDMO with proven hyaluronan capabilities and fresh commercial site transfers that can reaccelerate revenue. The balance sheet and recent guidance cut are real concerns, but the stock's valuation, contract pipeline and elevated short interest create an asymmetric trade for disciplined, risk-aware buyers.
T1 Energy's G2_Austin project is scheduled to materially ramp production and lower unit costs starting in 2027. If the build stays on schedule and commissioning delivers modeled throughput, the company should see a step-change in free cash flow that the market has not fully priced. This is a directional long trade with a measured stop and a multi-m…
Inhibrx (INBX) is a clinical-stage biotech with two near-term, high-impact catalysts: a PDUFA action date for ozekibart (INBRX-109) in April 2027 and Phase 2 PFS data for INBRX-106 expected in Q4 2026. The balance sheet ($161.7M cash after a $75M debt raise), improving operating losses and a market cap near $1.56B create an asymmetric risk/reward f…
Sandisk ($SNDK) is a high-quality NAND flash supplier trading near $1,546. The structural supply/demand story for NAND, recent industry commentary and bullish technicals create a favorable risk/reward for a mid-term long. This trade uses a precise entry, a disciplined stop and a realistic target tied to industry catalysts over the next 45 trading d…
Oracle is trading near $144 after a steep decline from last year's $329 high, while its cloud business and remaining performance obligations have exploded. This trade idea lays out a disciplined long: entry at $144.50, a protective stop at $125.00 and a target at $220.00, with time horizons and risk controls tied to capital intensity, customer conc…
MKS opened a 350,000 sq ft Supercenter in Penang and is expanding capacity in Guangzhou while analysts lift estimates. The stock has pulled back and presents a mid-term swing trade: enter at $245, target $320, stop $210. The plan captures a likely re-rating as factory-related revenue and bookings show through, while protecting against execution or …
WaterBridge Infrastructure (WBI) is a service-grounded infrastructure play with strong reported margins and a concentrated footprint across high-return U.S. shale basins. The stock sits near $32.50, offering a tradeable setup: buy on a disciplined entry, target a re-test of the 52-week high and multiple expansion, and protect capital against execut…
Ampco-Pittsburgh is a compact industrial play with two businesses - forged and cast engineered products and air & liquid processing. At roughly $160M market cap and an enterprise value near $298M, the stock sits well below its 52-week high after a volatile year. Recent contract wins at a subsidiary, elevated short interest and attractive EV/sales c…
Apple's new iPhone Duo is positioned as a meaningful premium upgrade that can add high-margin revenue, accelerate the replacement cycle, and boost Services monetization. We lay out a tactical long with entry at $195.00, target $230.00 and stop at $175.00, horizon focused on the next 45 to 180 trading days depending on catalyst realization.
Sonida Senior Living is shaping up for the next growth phase after closing its $1.8 billion acquisition of CNL Healthcare Properties. Revenue and occupancy have meaningfully improved, institutional ownership has jumped, and the stock sits below recent highs. The setup is actionable: a long at $39.50 with a $50 target and a $34 stop, horizon 180 tra…
Ormat's 1,835 MW operational portfolio, recent $989.5M revenue run-rate and a string of commercial wins (including a 150 MW Google-linked PPA) support a tactical long. Current technical oversold conditions, manageable float (~61.5M shares) and concentrated development optionality from Ormega100 and EGS deployments argue for upside into a re-rating.…
Cytokinetics' Myqorzo (aficamten) is an important commercial proof point, but slow early uptake, minimal revenue, and a valuation that implies blockbuster sales make the stock vulnerable to downside if growth disappoints. I lay out a mid-term short trade with clear entry, stop and target and explain the catalysts, valuation disconnects and risks th…
